Nuove tecniche di diagnostica per immagini: La pet/ct

L'obiettivo di questo studio è quello di mettere in luce i diversi fattori che, negli ultimi anni, hanno portato ad un impiego sempre più diffuso della PET in ambito clinico, in Italia e all'estero. La recente integrazione delle informazioni funzionali della PET con le informazioni morfologiche di una TC, mediante tomografi ibridi PET/CT, ha radicalmente cambiato l’approccio alla stadiazione e al follow-up dei pazienti, rendendo questa tecnica una delle massime espressioni della moderna diagnostica per immagini, al giorno d'oggi utilizzata principalmente in campo oncologico. Nei primi capitoli, dopo un breve richiamo alla struttura della materia, ai concetti di radiazione e decadimento radioattivo, si analizzano le apparecchiature e i principi di funzionamento della tecnica PET/TC. Successivamente, nel capitolo 4 sono illustrati i diversi tipi di radiofarmaci e le loro applicazioni, con un’attenzione particolare al PSMA, impiegato principalmente nei tumori alla prostata, reni, tiroide e mammella. Proprio alla cura e alla diagnosi del tumore alla prostata è dedicato il capitolo 5, con un breve confronto tra l’ormai accreditata PET/CT con 18F-Colina e l’innovativa Ga-PSMA PET/CT. Nel capitolo 6 si prendono in considerazione le procedure e i protocolli da seguire durante un esame PET/TC, le misure di preparazione, prevenzione e le precauzioni che pazienti e personale sanitario devono osservare. Nel capitolo 7, infine, un breve cenno alle ultime innovazioni tecnologiche: imaging ibrido PET/MRI e fotomoltiplicatori SiPM. Le fonti bibliografiche citate constano principalmente di articoli in lingua inglese pubblicati sul portale PubMed. Parte della documentazione relativa alla progettazione dell'apparecchiatura PET/CT e al suo utilizzo è, invece, stata fornita da personale dell'arcispedale Santa Maria Nuova di Reggio Emilia.

Synthesis, characterization and crystallization of bionanocomposites based on PLLA, PCL and nanocellulose

In recent years, environmental concerns and the expected shortage in the fossil reserves have increased further development of biomaterials. Among them, poly(lactide) PLA possess some potential properties such as good ability process, excellent tensile strength and stiffness equivalent to some commercial petroleum-based polymers (PP, PS, PET, etc.). This biobased polymer is also biodegradable and biocompatible However, one great disadvantage of commercial PLA is slow crystallization rate, which restricts its use in many fields. Using of nanofillers is viewed as an efficient strategy to overcome this problem. In this thesis, the effect of bionanofillers in neat PLA and in blends of poly (L-lactide)(PLA)/poly(ε-Caprolactone) (PCL) has been investigated. The used nanofillers are: poly(L-lactide-co-ε-caprolactone) and poly(L-lactide-b-ε-caprolactone) grafted on cellulose nanowhiskers and neat cellulose nanowhiskers (CNW). The grafting reaction of poly(L-lactide-co-caprolactone) and poly (L-lactide-b-caprolactone) on the nanocellulose has been performed by the grafting from technique. In this way the polymerization reaction it is directly initiated on the substrate surface. The condition of the reaction were chosen after a temperature and solvent screening. By non-isothermal an isothermal DSC analysis the effect of bionanofillers on PLA and 80/20 PLA/PCL was evaluated. Non-isothermal DSC scans show a nucleating effect of the bionanofillers on PLA. This effect is detectable during PLA crystallization from the glassy state. Cold crystallization temperature is reduced upon the addition of the poly(L-lactide-b-caprolactone) grafted on cellulose nanowhiskers that is most performing bionanofiller in acting as a nucleating agent. On the other hand, DSC isothermal analysis on the overall crystallization rate indicate that cellulose nanowhiskers are best nucleating agents during isothermal crystallization from the melt state. In conclusion, nanofillers have different behavior depending on the processing conditions. However, the efficiency of our nanofillers as nucleating agent was clearly demonstrated in both isothermal as in non-isothermal condition.

Novel materials for direct X-ray detectors based on semiconducting organic polymers

Conventional inorganic materials for x-ray radiation sensors suffer from several drawbacks, including their inability to cover large curved areas, me- chanical sti ffness, lack of tissue-equivalence and toxicity. Semiconducting organic polymers represent an alternative and have been employed as di- rect photoconversion material in organic diodes. In contrast to inorganic detector materials, polymers allow low-cost and large area fabrication by sol- vent based methods. In addition their processing is compliant with fexible low-temperature substrates. Flexible and large-area detectors are needed for dosimetry in medical radiotherapy and security applications. The objective of my thesis is to achieve optimized organic polymer diodes for fexible, di- rect x-ray detectors. To this end polymer diodes based on two different semi- conducting polymers, polyvinylcarbazole (PVK) and poly(9,9-dioctyluorene) (PFO) have been fabricated. The diodes show state-of-the-art rectifying be- haviour and hole transport mobilities comparable to reference materials. In order to improve the X-ray stopping power, high-Z nanoparticle Bi2O3 or WO3 where added to realize a polymer-nanoparticle composite with opti- mized properities. X-ray detector characterization resulted in sensitivties of up to 14 uC/Gy/cm2 for PVK when diodes were operated in reverse. Addition of nanoparticles could further improve the performance and a maximum sensitivy of 19 uC/Gy/cm2 was obtained for the PFO diodes. Compared to the pure PFO diode this corresponds to a five-fold increase and thus highlights the potentiality of nanoparticles for polymer detector design. In- terestingly the pure polymer diodes showed an order of magnitude increase in sensitivity when operated in forward regime. The increase was attributed to a different detection mechanism based on the modulation of the diodes conductivity.

Studies on ToF-PET using Cherenkov radiation

La tomografia ad emissione di positroni (PET) è una tecnica di imaging di medicina nucleare, utilizzata oggi diffusamente in ambito clinico. Essa fornisce immagini e informazioni fisiologiche dei processi funzionali all’interno del corpo. La PET si basa sulla rilevazione di fotoni di annichilazione prodotti in seguito al decadimento di un radio farmaco iniettato nel paziente. I rilevatori convenzionali sono costituiti da un materiale scintillatore accoppiato ad un fotomoltiplicatore, solitamente un PMT o SiPM. Uno sviluppo della PET è la Time of Flight PET (ToF PET), attualmente già in commercio ed utilizzata con prestazioni eccellenti. Un’ulteriore modifica, che potenzialmente permetterebbe di ottenere una migliore risoluzione temporale, è la ToF PET basata sulla rilevazione di fotoni tramite radiazione Cherenkov, invece che luce di scintillazione. Questo lavoro di tesi è incentrato dunque su questa tecnica specifica. Si illustra una rassegna di pubblicazioni scientifiche degli ultimi anni riguardo ad essa con i relativi risultati ottenuti e i possibili sviluppi futuri. Infine si propone un approfondimento personale, nel quale, tramite un programma scritto in ROOT, si è realizzata una geometria di un sistema di rilevazione ToF PET. Esso prevede la rilevazione dei fotoni di annichilazione tramite un radiatore Cherenkov accoppiato ad un SiPM. In futuro questo potrà essere implementato e utilizzato per simulare il processo fisico della PET, verificando la validità e le prestazioni del sistema così sviluppato.

Ricostruzione di gradienti di ossigeno e glucosio da immagini PET per applicazioni nanobiotecnologiche.

La ricerca biomedica è arrivata attualmente a un bivio che vede contrapposte sperimentazione in vitro e in vivo. Per ovviare a questo problema è nata la sperimentazione su biochip che, attraverso l'impiego di apparecchiature dedicate, permette di ottenere misure su campioni che ripropongano le condizioni fisiologiche dei tessuti umani in vivo superando il problema della sperimentazione animale e quello delle misure in vitro, che non rispecchiano le condizioni reali delle cellule in esame. Il perfezionamento dell'apparecchio in questione richiede la comparazione delle condizioni create nel biochip con quelle riscontrate nei tessuti cellulari di pazienti umani. Il fine della comparazione è quello di riuscire ad eguagliare i due sistemi per poter sfruttare il dispositivo come un fantoccio su cui verificare gli effetti di farmaci in fase sperimentale e misurare grandezze con un grado di precisione molto più alto rispetto ai metodi messi in opera fino a ora. Questo lavoro di tesi propone uno studio preliminare sulla fattibilità di misure di concentrazioni di ossigeno e glucosio attraverso i radiofarmaci 64Cu-ATSM e 18F-FDG impiegati su pazienti sottoposti a PET-CT. Nello specifico, dopo aver illustrato i processi cellulari che coinvolgono il glucosio e l'ossigeno all'interno dei tessuti umani, si passa a descrivere le metodologie di misura impiegate, nell'ambito dell'imaging diagnostico, e le caratteristiche che motivano la scelta dei radiofarmaci utilizzati come mezzo di contrasto. Successivamente viene considerato un modello compartimentale a due tessuti per descrivere la cinetica dei radiofarmaci e per ottenere una stima delle concentrazioni da rapportare alle grandezze rilevate con la PET. Infine sono tracciati dei profili sulle slice dei volumi PET elaborati che diano dei valori di concentrazione delle molecole studiate.

Biomimetic coating of organic polymers with a protein-functionalized layer of calcium phosphate: the surface properties of the carrier influence neither the coating characteristics nor the incorporation mechanism or release kinetics of the protein

Polymers that are used in clinical practice as bone-defect-filling materials possess many essential qualities, such as moldability, mechanical strength and biodegradability, but they are neither osteoconductive nor osteoinductive. Osteoconductivity can be conferred by coating the material with a layer of calcium phosphate, which can be rendered osteoinductive by functionalizing it with an osteogenic agent. We wished to ascertain whether the morphological and physicochemical characteristics of unfunctionalized and bovine-serum-albumin (BSA)-functionalized calcium-phosphate coatings were influenced by the surface properties of polymeric carriers. The release kinetics of the protein were also investigated. Two sponge-like materials (Helistat® and Polyactive®) and two fibrous ones (Ethisorb and poly[lactic-co-glycolic acid]) were tested. The coating characteristics were evaluated using state-of-the-art methodologies. The release kinetics of BSA were monitored spectrophotometrically. The characteristics of the amorphous and the crystalline phases of the coatings were not influenced by either the surface chemistry or the surface geometry of the underlying polymer. The mechanism whereby BSA was incorporated into the crystalline layer and the rate of release of the truly incorporated depot were likewise unaffected by the nature of the polymeric carrier. Our biomimetic coating technique could be applied to either spongy or fibrous bone-defect-filling organic polymers, with a view to rendering them osteoconductive and osteoinductive.

PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact

In a minority of cases a definite diagnosis and stage grouping in cancer patients is not possible based on the imaging information of PET/CT. We report our experience with percutaneous PET/CT-guided bone biopsies to histologically verify the aetiology of hypermetabolic bone lesions.

Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors

A variety of radiolabeled somatostatin analogs have been developed for targeting of somatostatin receptor (sst)-positive tumors. Bicyclic somatostatin-based radiopeptides have not been studied yet. Hypothesizing that the introduction of conformational constraints may lead to receptor subtype selectivity or may help to delineate structural features determining pansomatostatin potency, we developed and evaluated first examples of this new class of potential radiotracers for imaging or therapy of neuroendocrine tumors.

One-Step (18)F-Labeling of Carbohydrate-Conjugated Octreotate-Derivatives Containing a Silicon-Fluoride-Acceptor (SiFA): In Vitro and in Vivo Evaluation as Tumor Imaging Agents for Positron Emission Tomography (PET)

The synthesis, radiolabeling, and initial evaluation of new silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives is reported. So far, the main drawback of the SiFA technology for the synthesis of PET-radiotracers is the high lipophilicity of the resulting radiopharmaceutical. Consequently, we synthesized new SiFA-octreotate analogues derivatized with Fmoc-NH-PEG-COOH, Fmoc-Asn(Ac?AcNH-?-Glc)-OH, and SiFA-aldehyde (SIFA-A). The substances could be labeled in high yields (38 ± 4%) and specific activities between 29 and 56 GBq/?mol in short synthesis times of less than 30 min (e.o.b.). The in vitro evaluation of the synthesized conjugates displayed a sst2 receptor affinity (IC?? = 3.3 ± 0.3 nM) comparable to that of somatostatin-28. As a measure of lipophilicity of the conjugates, the log P(ow) was determined and found to be 0.96 for SiFA-Asn(AcNH-?-Glc)-PEG-Tyr³-octreotate and 1.23 for SiFA-Asn(AcNH-?-Glc)-Tyr³-octreotate, which is considerably lower than for SiFA-Tyr³-octreotate (log P(ow) = 1.59). The initial in vivo evaluation of [¹?F]SiFA-Asn(AcNH-?-Glc)-PEG-Tyr³-octreotate revealed a significant uptake of radiotracer in the tumor tissue of AR42J tumor-bearing nude mice of 7.7% ID/g tissue weight. These results show that the high lipophilicity of the SiFA moiety can be compensated by applying hydrophilic moieties. Using this approach, a tumor-affine SiFA-containing peptide could successfully be used for receptor imaging for the first time in this proof of concept study.

[The role of PET imaging in patients with lymphoma]

Positron-Emission-Tomography (PET) has emerged as a diagnostic gold standard for most tumor entities during the last 20 years, especially for patients suffering from malignant lymphoma. The development and distribution of machines allowing for hybrid imaging, i.e. the simultaneous acquisition of PET and CT datasets, and the possibility to assess even small pathologic findings with fused PET/CT image visualization, once more significantly improved the diagnostic accuracy of PET. Based on an excellent sensitivity the metabolic imaging with PET or PET/CT allows for a reliable overall assessment of patients with malignant lymphoma before therapy, for the early identification of non-responders during therapy, and for the diagnosis of relapse after therapy.

Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas

6-(18)F-fluoro-l-dopa ((18)F-FDOPA) measured with PET as a biomarker of amino acid uptake has been investigated in brain tumor imaging. The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas.

Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice

Transgenic mouse models of human cancers represent one of the most promising approaches to elucidate clinically relevant mechanisms of action and provide insights into the treatment efficacy of new antitumor drugs. The use of Trp53 transgenic mice (Trp53 knockout [Trp53(-/-)] mice) for these kinds of studies is, so far, restricted by limitations in detecting developing tumors and the lack of noninvasive tools for monitoring tumor growth, progression, and treatment response.

Dual-modality PET/CT instrumentation-today and tomorrow

Positron emission tomography (PET) has proven to be a clinically valuable imaging modality, particularly for oncology staging and therapy follow-up. The introduction of combined PET/CT imaging has helped address challenging imaging situations when anatomical information on PET-only was inadequate for accurate lesion localization. After a decade of PET/CT these combined systems have matured technically. Today, whole-body oncology staging is available with PET/CT in 15 min, or less. This review details recent developments in combined PET/CT instrumentation and points to implications for major applications in clinical oncology.